A Review on the Therapeutic Management of COVID-19 Associated with Thrombotic Events and Coagulopathies

Abstract

Severe acute respiratory syndrome coronavirus two (SARS-CoV-2) is answerable for the coronavirus illness in 2019 (COVID-19) that chop-chop evolved from a virus in metropolis, Varied coagulopathies are rumored in association with COVID-19, together with disseminated intavasular action (DIC) sepsis-induced coagulopathy (SIC), native microthrombi, blood vessel occulation (VTE), blood vessels thrombotic complications and thrombo inflammation. There’s a overplus of publications and conflicting information on hematologic and astringent derangements in COVID-19 with some information suggesting the link to illness progress, severity and/or mortality. There is also growing evidence of potentially usefull clinical biomarkers to predict COVID-19 progression and illness outcomes of these, a link between blood disease and COVID-19 severity or mortality was instructed. During this opinion report, we have a tendency to examine the revealed proof of hematological and astringent laboratory derangements in COVID-19 and also the reticular SARS-CoV-2 evoked inflammation, with a focused discussion on blood platelet count alterations.